arrow
P

Piotr Milkiewicz

Medical University of Warsaw
H指数:49
被引数:9,586

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Disease- and Region-Specific Molecular Patterns Involving miRNAs and Associated Signalling Pathways and Epithelial Cell-Fate Responses in PSC-Associated Ulcerative Colitis

PSC相关性溃疡性结肠炎中与miRNAs相关的疾病和区域特异性分子模式及其信号通路和上皮细胞命运应答

Cells
IF5.2
2026-10-080
OA
Elevated Polyreactive Immunoglobulin G in Immune-Mediated Liver Injuries With the Need for Immunosuppressive Therapy

免疫介导性肝损伤中升高的多反应性免疫球蛋白G及对免疫抑制疗法的需求

2026-03-080
OAAI
Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4−/− mice

白血病抑制因子促进人类胆管病,其抑制作用改善了Abcb4−/−小鼠的胆汁淤积

2025-08-260
OAAI
Mutational Analysis of Bile Cell-Free DNA in Primary Sclerosing Cholangitis: A Pilot Study

原发性硬化性胆管炎中胆汁游离DNA的突变分析: 一项初步研究

2025-04-010
OAAI
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4-/- Mice
2025-01-130
OAAI
COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls (Aug, 10.14309/ajg.0000000000003029, 2024)

COBALT:奥贝胆酸在原发性胆汁性胆管炎中的验证性试验(含安慰剂和外部对照)(Aug, 10.14309/ajg.0000000000003029, 2024)

2024-11-291
PRE
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
2024-11-011
OAAI
Efficacy and safety of infliximab in patients with autoimmune hepatitis
2024-09-060
PRE
Antimicrobial glycoprotein 2 (GP2) in gallstones, bile fluid and peribiliary glands of patients with primary sclerosing cholangitis
2024-08-010
OAAI
Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R-LIVER)

自身免疫性肝炎的未满足需求: 前瞻性多中心欧洲参考网络注册 (r-liver) 的结果

2024-07-224
OAAI
Increased type-I interferon level is associated with liver damage and fibrosis in primary sclerosing cholangitis
2024-03-010
OAAI